Awaiting results
A021806 — perioperative vs adjuvant mFOLFIRINOX in resectable PDAC
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
- Phase
- Phase III
- Recruitment
- Active, not recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT04340141
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? A trial asks whether giving chemotherapy before and after pancreas surgery is better than after surgery only.
Why promising? Randomizes whether perioperative therapy beats adjuvant-only mFOLFIRINOX in resectable PDAC.
What is not proven? Results unpublished; do not confuse with PRODIGE-24 adjuvant context.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; enrollment closed. Read maturity from primary publication.
Cancer / population: Pancreas — Rezeke edilebilir pankreas duktal adenokarsinomu
Intervention: Perioperatif mFOLFIRINOX
Primary endpoint: OS (protokol)
Limitations: Sonuç yok; unrezektabl/sınırda rezeke edilebilir ayrı.